Joined September 2013
- Tweets 1,896
- Following 88
- Followers 528
- Likes 407
105 Photos and videos
.@publiceye_ch lehnt die #KVV Vorlage zu Medikamentenpreisen in🇨đź‡ab. Die Einsparungen bleiben gering, solange nichts gegen die Machtasymmetrie zwischen #Pharma & @BAG_OFSP_UFSP unternommen wird. Es braucht eine grĂĽndlichere Reform und mehr Transparenz! publiceye.ch/de/news/detail/…
1
29
Unsere Recherchen zeigen die riesigen Profitmargen der #Pharma in der 🇨đź‡. Es besteht insbesondere bei hochpreisigen Medikamenten enormes Sparpotenzial, ohne dass dadurch die Innovation oder die Versorgungssicherheit gefährdet wĂĽrden. publiceye.ch/de/mediencorner…
50
Public Eye rejette le projet de rĂ©vision #OAMal sur le prix des mĂ©dicaments en🇨đź‡. Les Ă©conomies resteront modestes tant qu'on n'agira pas sur l'asymĂ©trie de pouvoir entre #pharma et @BAG_OFSP_UFSP. Il faut une rĂ©forme plus drastique & plus de transparence! publiceye.ch/fr/news/detail/…
1
30
Nos enquĂŞtes ont rĂ©vĂ©lĂ© des marges bĂ©nĂ©ficiaires gigantesques rĂ©alisĂ©es par la #pharma en🇨đź‡. Le potentiel d’économie est Ă©norme sur les mĂ©dicaments très chers – sans pour autant mettre en pĂ©ril l’innovation, l’approvisionnement ou leur viabilitĂ© financière publiceye.ch/fr/coin-medias/…
55
Patrick Durisch (@dbdurisch.bsky.social) retweeted
A new book by @realtahiramin and Rohit Malpani is now available in the U.S.
Pharma Monopoly: The Battle for the Future of Medicines examines the origins of outdated patent rules and economic policies that champion monopolies over the public interest.
🔗wiley.com/en-us/Pharma Monop…
3
9
278
Patrick Durisch (@dbdurisch.bsky.social) retweeted
May 27
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain.
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.” trib.al/DCQtAfp
6
4
346
Patrick Durisch (@dbdurisch.bsky.social) retweeted
The WHO is deciding this now. EU & Norway are to blame but they can change course.
We need a fair & equitable pathogen access and benefit-sharing system 🌍 #fairpabs
Sign fairpabs.org
1
30
A virus or bacteria's digital sequence information uploaded by a public lab in Recife or Nairobi re-emerges as intellectual property owned in the US or Europe.
No trace. No obligation. No return.
This injustice cannot go on. Sign the petition fairpabs.org #fairpabs
33
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Excellent @ICIJorg longform piece on #pharma drug pricing - specifically focused #Merck's secretive pricing of its blockbuster drug Keytruda.
icij.org/investigations/canc…
Worth flagging this part of it:
1
5
5
1,698
Thank you @realtahiramin @IMAKglobal for supporting
@PublicEyeSuisse in our patent analysis of cancer drug #Keytruda, in conjunction with @ICIJorg, unveiling Merck/MSD's gaming of the patent systems to maintain overinflated prices & delay competition publiceye.ch/en/topics/pharm…
Apr 14
What @ICIJorg found aligns with what we, and others, have found: Merck has built a multi-pronged patent abuse scheme to fortify its Keytruda monopoly and maintain high prices.
2
2
5
432
In this story, @publiceye_ch also shared with @ICIJorg an exclusive estimate of Merck/MSD's R&D costs for #pembrolizumab based on independent verifiable data. These represent just a tiny fraction of what MSD pretends ➡️$1.9bn vs >$30bn.
Check it out here👉publiceye.ch/en/topics/pharm…
2
44
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Apr 13
Publicamos la Investigación global "The Cancer Calculus" (icij.org/investigations/canc…), coordinada por @ICIJorg, con participación del equipo argentino: @iruiz, @halconada, @marielfitz, @spcrucianelli, @Emiliadelfino, @edlitvin y @rgbrom
elruido.org/argentina-un-cas…
3
6
1,388
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Apr 13
Este medicamento puede salvar vidas, pero se vende hasta dos veces más caro en #Guatemala que en Europa.
Mientras la farmacéutica Merck gana millones, pacientes con cáncer deben pelear contra el sistema para acceder a Keytruda, #LaMedicinaDelMillón. 💊 lnk.bio/s/a2daf
2
72
87
12,564
Patrick Durisch (@dbdurisch.bsky.social) retweeted
💸¿Por qué un fármaco contra el cáncer de #Merck es inaccesible para muchos pacientes?
#Pembrolizumab (Keytruda) cuesta US$65.000 por terapia en Perú si lo cubre el SIS, y el doble el privado. Una investigación de @ICIJorg, que integra #SaludConLupa, revela el negocio detrás.🧵
5
86
87
6,309
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Feb 19
Full set of Principles for Access to Medicines and Trade: citizen.org/news/more-than-1…
2
1
121
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Feb 19
The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines.
Experts from around the world offer an alternate vision:
ALT Teal background with highlighted quote: "Pro-corporate, pro monopoly models reinforced by the current trade order and exploited by the powerful are failing the world. Health must be a guarantee, not a bargaining chip." Blue background with caption: "Over 100 organizations around the world detail principles for trade that ensure access to medicines."
3
12
12
2,672
PlutĂ´t une vaste farce qu'un accord, un peu comme les soldes : des % en apparence Ă©levĂ©s mais sur des prix catalogue fictifs, avec un impact mineur pour les patient·e·s 🇺🇸 mais majeur pour #BigPharma. Qui exigera en retour une hausse indĂ©cente en🇨đź‡đź‡Şđź‡ş... rts.ch/info/economie/2025/ar…
1
36
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations insights.citeline.com/pink-s…
1
1
28
.@PublicEyeSuisse extensively reported about Roche's patent evergreening strategy on its breast cancer treatments trastuzumab & follow-on products. This led to complaints by competition authorities a.o. in South Africa. When will 🇨đź‡start to act? publiceye.ch/en/topics/pharm…
1
1
189
The $150bn question: has the 🇮🇳 gov considered introducing drug #dataexclusivity on its own, after resisting it for decades in trade talks? Or has🇨đź‡@SECO_StateSec helped by suggesting it could attract additional foreign investment, as reported by 🇮🇳 press? thehindubusinessline.com/new…
5 Dec 2025
🤝Angeregter Austausch mit Public Eye insbesondere zu Fragen des geistigen Eigentums und Testdatenschutz in 🇮🇳 und der Rolle der 🇨đź‡. Wir bleiben hierzu weiter im Gespräch.
1
90